News of Note—Teva accused of shortcutting plant sale; Sun plant gets only one observation

newspapers
(Pixabay)

> Teva has been sued by an Israeli businessman who claims his bid for the land use for two plants the drugmaker is closing in Jerusalem was overlooked. Story

> Sun Pharmaceutical has received on observation during a January FDA inspection of its plant in Halol. Form 483 (PDF)

> Strides says the FDA has approved a new dosage plant in Singapore. Filing (PDF)

> Shanghai-based WuXi STA has received EMA approval for a new drug product manufacturing facility in the Waigaoqiao Free Trade Zone of Shanghai. Release

> Lupin has received EU approval for a biologics plant in India. Story

> Cambrex says it has doubled the liquid filling capacity at its plant in Mirabel, Québec. Release

 

Suggested Articles

Hospital-backed Civica Rx has struck a deal for a CDMO to help it develop its own brand of drugs, for which it will own the rights.

South Korea’s Celltrion, which has a massive biologics site in Songdo, has decided it is time to build some operations in China.

WuXi Biologics is taking control of a Bayer plant in Germany and agreed it could serve as a backup facility for supply of hemophilia drug Kovaltry.